Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of cadonilimab, capecitabine, and oxaliplatin. Cadonilimab is a tetravalent bispecific monoclonal antibody that targets both programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), two key immune checkpoints. By blocking these pathways, it reinvigorates T cell activity against cancer cells and can overcome resistance to single-agent immunotherapies[1][2][5][7]. Capecitabine is an oral prodrug of fluorouracil, classified as an antimetabolite chemotherapy agent; it interferes with DNA synthesis in rapidly dividing cells[6][8]. Oxaliplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA replication and transcription. This triple-drug regimen leverages immunotherapy with dual checkpoint inhibition alongside cytotoxic chemotherapy to enhance anti-tumor efficacy. The combination has been investigated primarily in advanced or metastatic cancers such as gastric cancer and cervical cancer[5][7].
- Brand names
- Atyrso
- Other names
- Candonilimab + oxaliplatin + capecitabine
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cadonilimab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + capecitabine + oxaliplatin.